High-Activated NK Cell Therapy (NK Therapy)

NK (Natural Killer) cells play a critical role in the immune system by quickly identifying and attacking virus-infected cells and cancer cells. High-Activated NK Cell Therapy involves substantially expanding and activating NK cells outside the body, and then returning them into the patient's body.

Cancer cells sometimes evade attacks by cytotoxic T lymphocytes (CTLs)—which are trained to target them—by hiding their markers known as MHC class I molecules. However, NK cells can still target and attack these cancer cells using a receptor called NKG2D. This ability allows NK cells to complement the limitations of dendritic cell therapy and αβ T cell therapy.

Furthermore, NK cells exert antibody-dependent cellular cytotoxicity (ADCC), a mechanism that enhances the effectiveness of antibody-based drugs used in cancer treatment, such as Herceptin and Rituxan. Therefore, combining NK cell therapy with these molecular targeted therapies may lead to significantly improved treatment outcomes.

Treatment Flow